H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 307, Issue 2, 2014, Pages

  Raveendran, Vineesh V ^a   Kassel, Karen M ^b   Smith, Donald D ^a   Luyendyk, James P ^b,d   Williams, Kurt J ^d   Cherian, Rachel ^c   Reed, Gregory A ^b   Flynn, Colleen A ^b   Csanaky, Iván L ^b   Lickteig, Andrew L ^b   Pratt Hyatt, Matthew J ^b   Klaassen, Curtis D ^b   Dileepan, Kottarappat N ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Bile acids; Cetirizine; Fexofenadine; H1 antihistamines; Steatosis

Indexed keywords

BILE ACIDS; CETIRIZINE; FEXOFENADINE; H1-ANTIHISTAMINES; STEATOSIS;

ANIMALS; APOLIPOPROTEINS E; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CETIRIZINE; CHOLESTEROL ESTERS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION REGULATION; HISTAMINE H1 ANTAGONISTS; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; SEVERITY OF ILLNESS INDEX; TERFENADINE; TRIGLYCERIDES;

EID: 84904324210     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00027.2014     Document Type: Article

References (42)

1. Alnouti Y, Csanaky IL, Klaassen CD. Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 873: 209-217, 2008.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
3. Benarroch EE. Histamine in the CNS: multiple functions and potential neurologic implications. Neurology 75: 1472-1479, 2010.
4. Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, Ratziu V, Serfaty L, Housset C, Capeau J, Girard J, Guillou H, Postic C. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest 122: 2176-2194, 2012.
5. Bowes SG, Renwick AG. The hepatic metabolism and biliary excretion of benzo[a]pyrene in guinea-pigs fed normal, high-fat or high-cholesterol diets. Xenobiotica 16: 531-542, 1986.
6. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 50: 1955-1966, 2009.
7. Csanaky IL, Lu H, Zhang Y, Ogura K, Choudhuri S, Klaassen CD. Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice. Hepatology 53: 272-281, 2011.
8. Farese RV Jr, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 15: 570-573, 2012.
9. Flynn CA, Alnouti Y, Reed GA. Quantitation of the transporter substrate fexofenadine in cell lysates by LC-MS/MS. Rapid Commun Mass Spectrom 25: 2361-2366, 2011.
10. Fulop AK, Foldes A, Buzas E, Hegyi K, Miklos IH, Romics L, Kleiber M, Nagy A, Falus A, Kovacs KJ. Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. Endocrinology 144: 4306-4314, 2003.
11. Gao J, Katagiri H, Ishigaki Y, Yamada T, Ogihara T, Imai J, Uno K, Hasegawa Y, Kanzaki M, Yamamoto TT, Ishibashi S, Oka Y. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 56: 24-33, 2007.
12. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49: 71-87, 2010.
13. Jin H, Koyama T, Hatanaka Y, Akiyama S, Takayama F, Kawasaki H. Histamine-induced vasodilation and vasoconstriction in the mesenteric resistance artery of the rat. Eur J Pharmacol 529: 136-144, 2006.
14. Jutel M, Blaser K, Akdis CA. The role of histamine in regulation of immune responses. Chem Immunol Allergy 91: 174-187, 2006.
15. Karagiannides I, Abdou R, Tzortzopoulou A, Voshol PJ, Kypreos KE. Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J 275: 4796-4809, 2008.
16. Karavia EA, Papachristou DJ, Kotsikogianni I, Giopanou I, Kypreos KE. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice. FEBS J 278: 3119-3129, 2011.
17. Kis E, Ioja E, Rajnai Z, Jani M, Mehn D, Heredi-Szabo K, Krajcsi P. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs. Toxicol In Vitro 26: 1294-1299, 2012.
18. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 286: 1043-1050, 1998.
19. Kurose Y, Terashima Y. Histamine regulates food intake through modulating noradrenaline release in the para-ventricular nucleus. Brain Res 828: 115-118, 1999.
20. Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, Erickson SK, Chiang JY. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem 287: 1861-1873, 2012.
21. Lickteig AJ, Fisher CD, Augustine LM, Cherrington NJ. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol 21: 216-220, 2007.
22. Masaki T, Chiba S, Yoshimichi G, Yasuda T, Noguchi H, Kakuma T, Sakata T, Yoshimatsu H. Neuronal histamine regulates food intake, adiposity, and uncoupling protein expression in agouti yellow (A(y)/a) obese mice. Endocrinology 144: 2741-2748, 2003.
23. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 50: 376-384, 2001.
24. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 50: 385-391, 2001.
25. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoEdeficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14: 133-140, 1994.
26. Ndumele CE, Nasir K, Conceicao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 31: 1927-1932, 2011.
27. Panula P, Yang HY, Costa E. Histamine-containing neurons in the rat hypothalamus. Proc Natl Acad Sci USA 81: 2572-2576, 1984.
28. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol 147, Suppl 1: S127-S135, 2006.
29. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343-353, 1992.
30. Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring) 18: 2398-2400, 2010.
31. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008.
32. Sakata T, Yoshimatsu H, Kurokawa M. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 13: 403-411, 1997.
33. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33: 1477-1481, 2005.
34. Smith DD, Tan X, Raveendran VV, Tawfik O, Stechschulte DJ, Dileepan KN. Mast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice. Am J Physiol Heart Circ Physiol 302: H2612-H2621, 2012.
35. Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflügers Arch 453: 611-620, 2007.
36. Takahashi K, Suwa H, Ishikawa T, Kotani H. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest 110: 1791-1799, 2002.
37. Wang KY, Tanimoto A, Guo X, Yamada S, Shimajiri S, Murata Y, Ding Y, Tsutsui M, Kato S, Watanabe T, Ohtsu H, Hirano K, Kohno K, Sasaguri Y. Histamine deficiency decreases atherosclerosis and inflammatory response in apolipoprotein E knockout mice independently of serum cholesterol level. Arterioscler Thromb Vasc Biol 31: 800-807, 2011.
38. Wang KY, Tanimoto A, Yamada S, Guo X, Ding Y, Watanabe T, Watanabe T, Kohno K, Hirano K, Tsukada H, Sasaguri Y. Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. Am J Pathol 177: 713-723, 2010.
39. Watanabe T, Taguchi Y, Hayashi H, Tanaka J, Shiosaka S, Tohyama M, Kubota H, Terano Y, Wada H. Evidence for the presence of a histaminergic neuron system in the rat brain: an immunohistochemical analysis. Neurosci Lett 39: 249-254, 1983.
40. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124-131, 2011.
41. Yin M, Zhang L, Sun XM, Mao LF, Pan J. Lack of apoE causes alteration of cytokines expression in young mice liver. Mol Biol Rep 37: 2049-2054, 2010.
42. Zhang Y, Klaassen CD. Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J Lipid Res 51: 3230-3242, 2010.